PIM
MRNA icon

Profit Investment Management’s Moderna MRNA Stock Holding History

Profit Investment Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,786
Closed -$282K – 78
2024
Q4 		$282K Sell
6,786
-256
-4% -$12.2K 0.23% 76
2024
Q3 		$471K Sell
7,042
-725
-9% -$66.6K 0.37% 71
2024
Q2 		$922K Buy
7,767
+893
+13% +$113K 0.58% 55
2024
Q1 		$732K Hold
6,874
– – 0.41% 61
2023
Q4 		$684K Sell
6,874
-232
-3% -$19.5K 0.39% 61
2023
Q3 		$734K Sell
7,106
-202
-3% -$22.5K 0.52% 52
2023
Q2 		$888K Sell
7,308
-100
-1% -$13.3K 0.58% 49
2023
Q1 		$1.14M Sell
7,408
-888
-11% -$146K 0.75% 39
2022
Q4 		$1.49M Hold
8,296
– – 1.05% 33
2022
Q3 		$982K Hold
8,296
– – 0.75% 37
2022
Q2 		$1.19M Hold
8,296
– – 0.87% 37
2022
Q1 		$1.43M Buy
8,296
+6,474
+355% +$1.09M 0.88% 36
2021
Q4 		$462K Buy
+1,822
New +$533K 0.29% 67

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Profit Investment Management's MRNA Position: Q1 2025 in Review

Profit Investment Management sold out of Moderna (MRNA) in Q1 2025, closing a stake of 6,786 shares — an estimated $282K sold.

Profit Investment Management first reported a position in MRNA in Q4 2021 and held it in 13 quarters. The position peaked at $1.49M in Q4 2022. 694 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

  • Profit Investment Management reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
  • Profit Investment Management sold 6,786 Moderna shares in Q1 2025, an estimated $282K.
  • Profit Investment Management first reported a position in Moderna in Q4 2021 and held it in 13 quarters.
  • Profit Investment Management's Moderna position peaked at $1.49M in Q4 2022.
  • 694 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on Profit Investment Management's 13F filing for Q1 2025, filed 9 Apr 2025.